SeekingAlpha · Jan 20, 2026
BioCryst: A Changed And Interesting Thesis For 2026
The Astria acquisition introduces uncertainty for BioCryst. Read why I see no compelling reason to initiate a position in BCRX stock at current levels.
NASDAQ · ATXS
Astria Therapeutics, Inc.
Healthcare · Biotechnology
$12.58
Up+$0.00 (+0.00%)
Updated Nov 2, 2026, 6:23 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 737.53M
- P/E ratio
- -6.41
- Dividend yield
- 0.00%
- 52-week range
- $3.56 – $13.29
- Volume
- 3.2M
- Avg. volume
- 1.97M
Price performance · ATXS
ATXS price history
1M range · 0 trading sessions · Daily adjusted prices
ATXS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ATXS news
The latest Smart Investors Daily articles mentioning ATXS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATXS research
Overview
Company profile and research snapshot.
Company profile
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 12, 2025 | Cantor Fitzgerald | Neutral | — |
| Oct 16, 2025 | HC Wainwright & Co. | Neutral | — |
| Oct 15, 2025 | Wedbush | Neutral | — |
| Oct 15, 2025 | JMP Securities | Market Perform | — |
| Oct 14, 2025 | Jefferies | Hold | — |
News briefing
No generated briefing is available yet.
prnewswire.com · Dec 1, 2025
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
